Posted by kalkgrun on 25th of Jun 2026 at 02:28 pm
Target $30 GLP-1 Maintence
Charting Omada’s margin trajectory relative to Hinge shows the
company is very much on the right track. One of the biggest
pushbacks we hear on OMDA is the company’s slim margins today. A
common question is how much does scale play in the margin
differential between Omada Health and Hinge Health. We looked at
how efficient the companies were running at similar revenue bases
(Hinge 2023 revenue of $293mn vs. Omada 2025 revenue of $260mn) to
shed light on this key debate – see
Exhibit 3. In addition to driving upside to revenue (2026
guidance calls for 25% y/y growth and we estimate 23% growth in
2027E), key levers for margin expansion at Omada are: 1) Keeping
care team headcount relatively flat as the company further flexes
the use of technology 2) Bringing down G&A as a percent of
revenue as the business scales (of note, this metric is currently
running 500 bps above that of Hinge) and 3) GLP-1 Prescribing
provides a 2.5x revenue uplift over standard GLP-1 Care Track at
high incremental margins, while also helping to broaden its funnel
of multi-condition sales.
We’re Overweight OMDA on a tipping point for cross-selling of
multiple programs, which has positive implications for durability
of growth and an inflection in margins. In addition to GLP-1 care
track serving to extend momentum in its longest standing segment of
Prevention and Weight Health (~75% of revenue), our checks point to
positive customer feedback on Hypertension (~13%) and Diabetes
(~12%). Omada is effectively leveraging technology and AI to scale
the platform, leading to a ~25% increase in total members per
coach. This can be seen in the meaningful 1100 bps expansion in GM
to 63.2% the past 2 years and gives us confidence in the company’s
longer term target of 70%+.
OMDA update
OMDA GLP-1 Care Track
Posted by kalkgrun on 25th of Jun 2026 at 02:28 pm
Target $30 GLP-1 Maintence
Charting Omada’s margin trajectory relative to Hinge shows the company is very much on the right track. One of the biggest pushbacks we hear on OMDA is the company’s slim margins today. A common question is how much does scale play in the margin differential between Omada Health and Hinge Health. We looked at how efficient the companies were running at similar revenue bases (Hinge 2023 revenue of $293mn vs. Omada 2025 revenue of $260mn) to shed light on this key debate – see Exhibit 3. In addition to driving upside to revenue (2026 guidance calls for 25% y/y growth and we estimate 23% growth in 2027E), key levers for margin expansion at Omada are: 1) Keeping care team headcount relatively flat as the company further flexes the use of technology 2) Bringing down G&A as a percent of revenue as the business scales (of note, this metric is currently running 500 bps above that of Hinge) and 3) GLP-1 Prescribing provides a 2.5x revenue uplift over standard GLP-1 Care Track at high incremental margins, while also helping to broaden its funnel of multi-condition sales.
OMDA made the IBD 50 and
Posted by kalkgrun on 10th of Jul 2026 at 09:31 am
OMDA made the IBD 50 and the IPO Leaders list
OMDA great earnings +15 target
Posted by kalkgrun on 7th of Aug 2026 at 11:05 am
OMDA great earnings +15 target $30
We’re Overweight OMDA on a tipping point for cross-selling of multiple programs, which has positive implications for durability of growth and an inflection in margins. In addition to GLP-1 care track serving to extend momentum in its longest standing segment of Prevention and Weight Health (~75% of revenue), our checks point to positive customer feedback on Hypertension (~13%) and Diabetes (~12%). Omada is effectively leveraging technology and AI to scale the platform, leading to a ~25% increase in total members per coach. This can be seen in the meaningful 1100 bps expansion in GM to 63.2% the past 2 years and gives us confidence in the company’s longer term target of 70%+.
OMDA
Posted by kalkgrun on 10th of Aug 2026 at 03:40 pm
Still looking good after the big volume Friday
yep man, looks good
Posted by matt on 10th of Aug 2026 at 03:46 pm
yep man, looks good